Nahdi Medical Company (4164.SR) — Cash flow
Operating, investing, and financing cash flow for Nahdi Medical Company — annual and quarterly.
| Metric (SAR Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | 831↓0.5% | 835↓11.6% | 944↑0.7% | 938↑9.4% | 857 | |
| Depreciation & Amortization | 781↑11.0% | 703↑13.8% | 618↑3.6% | 597↑4.4% | 572 | |
| Deferred Income Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stock-Based Compensation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes in Working Capital | -545↓4715.1% | -11↑92.7% | -155↓395.3% | 52↑491.7% | -13 | |
| Accounts Receivable | -129↓442.6% | 38↑198.4% | -38↓653.6% | 7↑114.5% | -48 | |
| Inventory | -628↓88.3% | -334↓55.5% | -215↓69.0% | -127↓247.9% | 86 | |
| Accounts Payable | 170↓52.0% | 354↑37.8% | 257↑67.9% | 153↑250.2% | 44 | |
| Other Working Capital | 42↑160.0% | -69↑56.5% | -159↓919.9% | 19↑120.4% | -95 | |
| Other Non-Cash Items | 127↑460.4% | -35↑8.5% | -39↓147.7% | 81↑199.3% | -81 | |
| Net Cash from Operating Activities | 1,194↓19.9% | 1,491↑9.0% | 1,369↓17.9% | 1,668↑25.0% | 1,334 | |
| Operating Cash Flow | 1,194↓19.9% | 1,491↑9.0% | 1,369↓17.9% | 1,668↑25.0% | 1,334 | |
| Investing Activities | ||||||
| Investment in Property, Plant & Equipment | -418↓23.0% | -340↑4.0% | -354↓28.6% | -275↑10.2% | -306 | |
| Capital Expenditure | -387↓0.7% | -384↑0.0% | -385↓39.7% | -275↑10.2% | -306 | |
| Acquisitions | 0.49 | 0.00 | 0.00↓100.0% | 0.10↓98.5% | 7 | |
| Purchases of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Sales & Maturities of Investments | 3 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Investing Activities | 0.00↓100.0% | 12↑137.9% | -30↓22.2% | -25↓48.1% | -17 | |
| Net Cash from Investing Activities | -414↓26.4% | -328↑14.6% | -384↓39.7% | -275↑8.1% | -299 | |
| Financing Activities | ||||||
| Net Debt Issuance | 0.00↑100.0% | -402 | 0.00 | 0.00 | 0.00 | |
| Long-Term Net Debt Issuance | 0.00↑100.0% | -402 | 0.00 | 0.00 | 0.00 | |
| Short-Term Net Debt Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Common Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Share Buybacks | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Preferred Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends Paid | -728↓1.8% | -715↑0.0% | -715↓138.1% | -300↑76.2% | -1,260 | |
| Common Dividends Paid | -728↓1.8% | -715↑0.0% | -715↓138.1% | -300↑76.2% | -1,260 | |
| Preferred Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Financing Activities | -454 | 0.00↑100.0% | -436↓4.5% | -417↓9.1% | -382 | |
| Net Cash from Financing Activities | -1,182↓5.8% | -1,117↑2.9% | -1,151↓60.4% | -717↑56.3% | -1,642 | |
| Cash Reconciliation | ||||||
| Effect of Foreign Exchange | 0.19↓75.8% | 0.77↑271.6% | -0.45↓113.1% | -0.21↓793.5% | -0.02 | |
| Net Change in Cash | -402↓953.4% | 47↑128.3% | -167↓124.7% | 675↑211.2% | -607 | |
| Cash at Beginning of Period | 957↑5.2% | 910↓15.5% | 1,076↑168.4% | 401↓60.2% | 1,009 | |
| Cash at End of Period | 554↓42.1% | 957↑5.2% | 910↓15.5% | 1,076↑168.4% | 401 | |
| Income Taxes Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow | 807↓27.1% | 1,107↑12.5% | 984↓29.3% | 1,393↑35.5% | 1,028 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.